



# 2026 NCODA INTERNATIONAL SPRING FORUM

## Essential CE Information

### CE Registration:

- Please make sure to register for the 2026 NCODA International Spring Forum CEs via this link: <https://www.lecturepanda.com/r/2026NCODASpringForum>
  - After registering for your CE, you should receive a confirmation email with a unique link. **Please DO NOT share this link with anyone as it is unique to your own profile.**
- You may also register for the 2026 NCODA International Spring Forum CEs via this QR code:



### CE Pre-assessment:

- After registering for your selected CEs, please make sure to complete each of your CE sessions' Pre-assessment **BEFORE** the start of each of those CE sessions
  - This is because the Pre-assessment will automatically close out 15 minutes **AFTER** each CE session, in order to prevent obtaining invalid data from participants completing the Pre-assessment after the CE session has ended

### Obtaining CE Credit:

- Credit requirements must be completed within 60 days of the program activity date: **June 16<sup>th</sup>, 2026**
- Upon completion, credit will be transmitted electronically to ACPE for pharmacists and pharmacy technicians
  - If you are a nurse, physician, or advanced practice provider, NCODA has partnered with Partners for Advancing Clinical Education (PACE) to expand CE accreditation
    - Please refer to the “PACE Handout” for more information

# 2026 NCODA International Spring Forum

## Physician, Nurse, and Advanced Practice Provider Sessions

### CE Information

April 15-17, 2026 | Denver, CO

Provided by Partners for Advancing Clinical Education and NCODA

#### **Target Audience**

This conference is intended for oncology healthcare providers that include; pharmacists, pharmacy technicians, physicians and nurses who care for patients within oncology

#### **Session Educational Objectives**

Upon completion of this session, participants should be able to:

#### **Blueprint to Brilliance: A Workshop on Crafting Your Career Path & Building a Technician Advancement Framework**

*1.0 AMA PRA Category 1 Credit™ and ANCC contact hour*

- Identify common practice-based challenges and opportunities related to oncology technician role optimization, including its impact on multidisciplinary oncology team performance.
- Describe how intentional technician role clarity and advancement can improve workflow efficiency, support top-of-license practice, and enhance care coordination.
- Discuss practical approaches for communicating technician value and workforce impact within multidisciplinary oncology teams and healthcare leadership structures.
- Outline a structured approach to identifying technician role optimization opportunities that support multidisciplinary team function and patient care delivery.
- Summarize how certification and advanced technician competencies contribute to standardized processes, patient safety, and quality-driven oncology care.

#### **Oncology Optimized Limited Distribution Workshop: Operationalizing Within Practice**

*1.0 AMA PRA Category 1 Credit™ and ANCC contact hour*

- Define the various distribution models for oncology medications.
- Discuss how the distribution models impact patient care.
- Identify how distribution barriers appear in practice operations.
- Describe the role of Oncology Optimized Limited Distribution (OOLD) for practices and patients.
- Review how medically integrated practices support coordination of combination therapy (oral and parenteral).

#### **Bridging Coverage and Care in 2026: Medicare OOP Changes, MP3, and Patient Financial Support**

*0.75 AMA PRA Category 1 Credit™ and ANCC contact hour*

- Describe the major updates to the Medicare Part D benefit in 2026—including changes to the deductible, initial coverage period, and catastrophic phase—and discuss how these modifications influence patients' out of pocket expenses.
- Explain the purpose and structure of the Medicare Prescription Payment Plan (M3P), including patient participation benefits.
- Identify common financial barriers and resources to support oncology patient access to therapy for those under the 2026 Medicare Part D redesign.
- Discuss the roles of the oncology multidisciplinary team in supporting patients through Medicare coverage changes and affordability challenges.

- Recognize key considerations for incorporating Medicare benefit changes and payment smoothing options into patient education and care coordination processes.

### **Protecting Access to Oncology-Optimized Limited Distribution Drugs**

*0.75 AMA PRA Category 1 Credit™ and ANCC contact hour*

- Discuss how medically integrated pharmacy workflows support coordination, monitoring, and continuity for oral and combination oncology regimens.
- Review the different distribution channels for oncology drugs, and how each one potentially affects patient care.
- Describe common operational barriers that limit a practice's ability to implement Oncology Optimized Limited Distribution (OOLD) therapies.
- Review practical strategies for routing, escalation, and payer override workflows to protect timely access to OOLD medications.

### **1:45-2:45 pm Breakout Sessions**

*1.0 AMA PRA Category 1 Credit™ and ANCC contact hour*

Right Test, Right Treatment, Right Time: Navigating Lung Cancer Diagnostics, Decisions, & Supportive Care

- List the key diagnostic tests and biomarkers used to stage and classify non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
- Explain how staging results and biomarker profiles influence treatment planning decisions for patients with NSCLC and SCLC.
- Describe evidence-based navigation strategies that minimize care delays and enhance interdisciplinary communication in lung cancer care coordination.
- Identify the supportive care needs and clinical interventions for patients receiving common NSCLC treatment regimens, including chemotherapy, targeted therapy, and immunotherapy.

### **2:45-3:45 pm Breakout Sessions (concurrent)**

*1.0 AMA PRA Category 1 Credit™ and ANCC contact hour*

Evolving Treatment Paradigms in Bladder Cancer Across the Care Continuum

- Summarize recently approved and emerging bladder-sparing therapies for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), including systemic and intravesical treatment options
- Explore emerging data supporting the use of enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer (MIBC), including perioperative strategies and implications for cisplatin-eligible and cisplatin-ineligible patients.
- Review current treatment strategies and sequencing considerations in locally advanced and metastatic urothelial carcinoma, including integration of antibody-drug conjugates and immunotherapy combinations based on recent clinical trial data.
- Discuss evolving administration strategies for immune checkpoint inhibitors, including intravenous and subcutaneous formulations of pembrolizumab and nivolumab, and their potential impact on patient care and clinic workflow.
- Recognize key adverse effects and mitigation strategies associated with immune checkpoint inhibitors and antibody-drug conjugates used in bladder cancer treatment.

The Journey of Self Development: Building Resilience and Well-Being for Oncology Clinicians

- Explain the established connection between clinician well-being and patient outcomes in oncology care.
- List the six pillars of lifestyle medicine and six resilience drivers relevant to oncology clinician well-being.
- Describe how to attain emotional regulation in the clinical setting to reduce burnout.
- Interpret how peer support mechanisms function as protective factors against burnout.

## Leveraging Your Toolbox: Strategies for Navigating 2026 Barriers - Accumulators, Maximizers & Alternate Funding Programs

- Describe how accumulators, maximizers, and alternative funding programs (AFPs) function as well as their impact on patient treatment access and affordability.
- Recognize early indicators of treatment access barriers within insurance benefit structures and coverage investigations.
- Explain workflow and communication strategies that may help minimize treatment delays associated with financial access challenges.
- Discuss practical support strategies and patient assistance resources used to help patients navigate accumulators, maximizers, and AFPs.

## From Referral to Randomization: Using AI to Close Clinical Trial Enrollment Gaps

### 1.0 AMA PRA Category 1 Credit™ and ANCC contact hour

- Describe the basic principles of how artificial intelligence (AI)-driven tools identify and match eligible patients for clinical trials in community oncology settings.
- Recognize common barriers to clinical trial enrollment
- Recall how AI-enabled processes can support access to care and promote health equity across diverse populations.
- Identify key opportunities for AI to enhance interdisciplinary collaboration among oncology research coordinators, nurses, advanced practice providers, pharmacists, physicians, pharmacy technicians and administrative teams.
- List examples of AI-integrated workflows used from referral through randomization and associated practice-level outcomes observed in real-world settings.

## Burnout in the Oncology Landscape: Challenges, Causes, and Solutions

### 0.75 AMA PRA Category 1 Credit™ and ANCC contact hour

- Describe the scope and impact of burnout among the multidisciplinary oncology team.
- Explain key drivers of burnout in oncology, including emotional demand, workload, and administrative burden, as well as their effects on patient safety, communication, and workforce stability.
- Discuss practical, evidence-based strategies at the individual, team, and system levels to help address burnout in oncology.

## Recognize, Triage, Treat: A Practical Approach to ICI Toxicities

### 0.75 AMA PRA Category 1 Credit™ and ANCC contact hour

- Recognize immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy.
- Identify the three most common tissues affected by irAEs.
- Discuss current recommendation for the treatment of patients with pre-existing autoimmune disease.
- Describe common treatment approaches used to manage irAEs from immune checkpoint inhibitor therapy.
- Explain the relationship between irAEs and cancer survival outcomes.

## Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

<b>Faculty/Planning Committee Member</b>	<b>Relevant Financial Relationship(s)</b>
Christopher Elder	Advisory Board Member: Pfizer, Pharmacosmos, Sanofi, Mirati, Novartis, Boehringer Ingelheim
Scott Freeswick	Advisory Board Member: Sanofi/Genzyme, Kura, Merck, Genmab, Janseen, AVYXA
Lucio Gordan	Speaker: BeOne; Stockholder: Core Ventures
Melissa Lechner	Consultant: Immunovant
Arturo Loaiza-Bonilla	Speaker: Guardant; Founder: Massive Bio; Consultant: AstraZeneca, PSI CRO; Advisory Board Member: HEARTio
Christi Miller	Consultant: PrescribePlus
Stephanie Parker	Advisory Board Member: AVEO, Partner Therapeutics, Nuvation Bio
Michael Reff	Speaker: J&J
Andrew Ruplin	Other: MJH Life Sciences, Dedham Group
Timothy Schieber	Principal Investigator: Pfizer; Co-Principal Investigator: BMS
Debra Shapert	Advisory Board Member: GSK, USON, Nuvalent

All other **faculty** and **planning committee members** have no relevant financial relationships.

### **Joint Accreditation Statement**

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and NCODA. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### **Physician Continuing Education**

Partners designates this live activity for a maximum of 8.0 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **PA Continuing Medical Education**



Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 8.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

### **Nursing Continuing Professional Development**

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 8.0 contact hours.

### **Disclosure of Unlabeled Use**

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not

necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

**Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

**Instructions for Credit**

CE Credit for the 2026 Spring Forum can be claimed through the LecturePanda platform. To register, please visit: <https://www.lecturepanda.com/r/2026NCODASpringForum>